Literature DB >> 27667180

Good things come in small packages: Overcoming challenges to harness extracellular vesicles for therapeutic delivery.

Dominique Ingato1, Jong Uk Lee2, Sang Jun Sim3, Young Jik Kwon4.   

Abstract

Extracellular vesicles (EVs) hold great promise as potential therapeutic carriers. EVs are biologically active, intrinsically transporting cargo between cells. Moreover, they can be loaded with specific cargo for distribution and/or engineered to achieve enhanced uptake. Although studies have already demonstrated therapeutic delivery using EVs, various challenges must be overcome before EV technology is ready for the clinic. Since the properties of EVs are dependent upon their cell of origin and the conditions of their formation, establishing clear characterization practices is essential to ensuring reproducibility and safety. Identifying methods for mass production of EVs is crucial for achieving high EV yields necessary for clinical trials. This review introduces current theory behind EV formation and function, describes the latest methods for characterization and mass production, and discusses future opportunities for extracellular vesicles in therapeutic delivery.
Copyright © 2016 Elsevier B.V. All rights reserved.

Keywords:  Exosomes; Extracellular vesicles; Microvesicles; Therapeutic delivery

Mesh:

Substances:

Year:  2016        PMID: 27667180     DOI: 10.1016/j.jconrel.2016.09.016

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  40 in total

1.  Mesenchymal Stem Cell-derived Extracellular Vesicles for Renal Repair.

Authors:  Arash Aghajani Nargesi; Lilach O Lerman; Alfonso Eirin
Journal:  Curr Gene Ther       Date:  2017       Impact factor: 4.391

Review 2.  Achieving the Promise of Therapeutic Extracellular Vesicles: The Devil is in Details of Therapeutic Loading.

Authors:  Dhruvitkumar S Sutaria; Mohamed Badawi; Mitch A Phelps; Thomas D Schmittgen
Journal:  Pharm Res       Date:  2017-03-17       Impact factor: 4.200

3.  High yield, scalable and remotely drug-loaded neutrophil-derived extracellular vesicles (EVs) for anti-inflammation therapy.

Authors:  Jin Gao; Sihan Wang; Zhenjia Wang
Journal:  Biomaterials       Date:  2017-05-03       Impact factor: 12.479

Review 4.  Exosomes in Myocardial Repair: Advances and Challenges in the Development of Next-Generation Therapeutics.

Authors:  Marta Adamiak; Susmita Sahoo
Journal:  Mol Ther       Date:  2018-05-03       Impact factor: 11.454

Review 5.  Cell membrane-derived nanoparticles: emerging clinical opportunities for targeted drug delivery.

Authors:  Svetlana T Yurkin; Zhenjia Wang
Journal:  Nanomedicine (Lond)       Date:  2017-07-26       Impact factor: 5.307

6.  Exosomes Serve as Nanoparticles to Deliver Anti-miR-214 to Reverse Chemoresistance to Cisplatin in Gastric Cancer.

Authors:  Xinyi Wang; Haiyang Zhang; Ming Bai; Tao Ning; Shaohua Ge; Ting Deng; Rui Liu; Le Zhang; Guoguang Ying; Yi Ba
Journal:  Mol Ther       Date:  2018-01-08       Impact factor: 11.454

Review 7.  Generation, purification and engineering of extracellular vesicles and their biomedical applications.

Authors:  Jin Gao; Xinyue Dong; Zhenjia Wang
Journal:  Methods       Date:  2019-11-30       Impact factor: 3.608

Review 8.  Strategic design of extracellular vesicle drug delivery systems.

Authors:  James P K Armstrong; Molly M Stevens
Journal:  Adv Drug Deliv Rev       Date:  2018-06-28       Impact factor: 15.470

9.  Sequential deletion of CD63 identifies topologically distinct scaffolds for surface engineering of exosomes in living human cells.

Authors:  Natalie Curley; Daniel Levy; Mai Anh Do; Annie Brown; Zachary Stickney; Gerard Marriott; Biao Lu
Journal:  Nanoscale       Date:  2020-06-11       Impact factor: 7.790

Review 10.  Mesenchymal Stem Cell-Derived Extracellular Vesicles: A Potential Therapeutic Strategy for Acute Kidney Injury.

Authors:  Jia-Kun Li; Cheng Yang; Ying Su; Jing-Chao Luo; Ming-Hao Luo; Dan-Lei Huang; Guo-Wei Tu; Zhe Luo
Journal:  Front Immunol       Date:  2021-06-03       Impact factor: 8.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.